[go: up one dir, main page]

AR105812A1 - Métodos para la preparación de inhibidores de proteína deacetilasa - Google Patents

Métodos para la preparación de inhibidores de proteína deacetilasa

Info

Publication number
AR105812A1
AR105812A1 ARP160101701A ARP160101701A AR105812A1 AR 105812 A1 AR105812 A1 AR 105812A1 AR P160101701 A ARP160101701 A AR P160101701A AR P160101701 A ARP160101701 A AR P160101701A AR 105812 A1 AR105812 A1 AR 105812A1
Authority
AR
Argentina
Prior art keywords
compound
formula
preparation
deacetilase
inhibitors
Prior art date
Application number
ARP160101701A
Other languages
English (en)
Inventor
H Van Duzer John
Seyedi Farzaneh
Original Assignee
Acetylon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acetylon Pharmaceuticals Inc filed Critical Acetylon Pharmaceuticals Inc
Publication of AR105812A1 publication Critical patent/AR105812A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30Halogen atoms or nitro radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Reivindicación 1: Un método para la preparación del compuesto de fórmula (1), que comprende los pasos de: la conversión del compuesto de fórmula (2) en el compuesto de fórmula (3); en el que X se selecciona de flúor, cloro, bromo y yodo; Z se selecciona del grupo que consiste en -CN y -CO₂R; y R es alquilo C₁₋₆; y la conversión del compuesto de fórmula (3) en el compuesto de fórmula (1). Reivindicación 20: Una composición que comprende un compuesto de fórmula (4); en la que Z se selecciona del grupo que consiste en CN y -CO₂R; y en la que R es alquilo C₁₋₆; y un compuesto de fórmula (5), en la que Z se selecciona del grupo que consiste en -CN y CO₂R; y en la que R es alquilo C₁₋₆. Reivindicación 24: Un compuesto que tiene la estructura de fórmula (6) en el que Z se selecciona del grupo que consiste en -CN y -CO₂R; y en el que R es alquilo C₁₋₆. Reivindicación 27: Una composición que comprende el compuesto de acuerdo con la reivindicación 24.
ARP160101701A 2015-06-08 2016-06-08 Métodos para la preparación de inhibidores de proteína deacetilasa AR105812A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562172624P 2015-06-08 2015-06-08

Publications (1)

Publication Number Publication Date
AR105812A1 true AR105812A1 (es) 2017-11-15

Family

ID=56264043

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160101701A AR105812A1 (es) 2015-06-08 2016-06-08 Métodos para la preparación de inhibidores de proteína deacetilasa

Country Status (11)

Country Link
US (1) US10144714B2 (es)
EP (1) EP3303304B1 (es)
JP (1) JP6873053B2 (es)
CN (1) CN107922352B (es)
AR (1) AR105812A1 (es)
AU (2) AU2016276573A1 (es)
CA (1) CA2988594C (es)
ES (1) ES2769255T3 (es)
MX (1) MX369349B (es)
TW (1) TWI706937B (es)
WO (1) WO2016200930A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3091004B1 (en) 2010-01-22 2017-12-13 Acetylon Pharmaceuticals, Inc. Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof
JP2015515279A (ja) 2012-04-19 2015-05-28 アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. 治療に反応する患者を同定するバイオマーカーおよびそのような患者の治療
JP6816036B2 (ja) 2015-06-08 2021-01-20 アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. ヒストン脱アセチル化阻害剤の結晶形態
WO2016200930A1 (en) 2015-06-08 2016-12-15 Acetylon Pharmaceuticals, Inc. Methods of making protein deacetylase inhibitors
TW201803594A (zh) * 2016-06-09 2018-02-01 達納-法伯癌症協會 Hdac抑制劑與bet抑制劑之使用方法及醫藥組合
JP7100018B2 (ja) 2016-08-08 2022-07-12 アセチロン ファーマシューティカルズ インコーポレイテッド ヒストンデアセチラーゼ6阻害剤及びcd20阻害抗体の薬学的組み合わせならびにその使用
JP7090611B2 (ja) 2016-11-23 2022-06-24 アセチロン ファーマシューティカルズ インコーポレイテッド ヒストン脱アセチル化酵素阻害剤とプログラム細胞死リガンド1(pd-l1)阻害剤とを含む医薬組み合わせ物及びその使用方法

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
ATE489360T1 (de) 2000-03-24 2010-12-15 Methylgene Inc Inhibitoren der histon-deacetylase
US20050119305A1 (en) 2001-03-21 2005-06-02 Masao Naka Il-6 production inhibitors
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
BR0213791A (pt) 2001-11-01 2004-12-07 Janssen Pharmaceutica Nv Derivados de amida como inibidores de glicogênio sintase quinase 3-beta
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
CA2518318A1 (en) 2003-03-17 2004-09-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
CA2531661C (en) 2003-07-07 2013-03-12 Georgetown University Histone deacetylase inhibitors and methods of use thereof
JP4993374B2 (ja) 2004-04-05 2012-08-08 メルク エイチディーエーシー リサーチ エルエルシー ヒストン脱アセチル化酵素インヒビタープロドラッグ
CA2601706C (en) 2005-03-22 2016-09-20 Dana-Farber Cancer Institute, Inc. Treatment of protein degradation disorders
KR20080052611A (ko) 2005-08-26 2008-06-11 메틸진 인크. 히스톤 탈아세틸 효소의 벤조디아제핀 및 벤조피페라진유도체 억제제
EP1991247B1 (en) 2006-02-14 2015-10-14 President and Fellows of Harvard College Bifunctional histone deacetylase inhibitors
AU2007248656B2 (en) 2006-05-03 2013-04-04 Dana-Farber Cancer Institute, Inc. Histone deacetylase and tubulin deacetylase inhibitors
WO2007144341A1 (en) 2006-06-12 2007-12-21 Vrije Universiteit Brussel Differentiation of rat liver epithelial cells into hepatocyte-like cells
ES2288802B1 (es) 2006-07-07 2008-12-16 Universidad De Granada Nuevos derivados de ftalimida como inhibidores de las histonas desacetilasas.
CA2662580C (en) 2006-09-11 2013-05-21 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
TWI478709B (zh) 2008-02-19 2015-04-01 Earnest Medicine Co Ltd A useful oral or enteral composition for the recovery of bodily functions
EP2321264B1 (en) 2008-07-23 2016-05-04 President and Fellows of Harvard College Deacetylase inhibitors and uses thereof
JP5713999B2 (ja) 2009-05-15 2015-05-07 コリア リサーチ インスティテュート オブ ケミカル テクノロジー アミド化合物、その製造方法及びそれを含む薬学組成物
WO2011019393A2 (en) 2009-08-11 2011-02-17 President And Fellows Of Harvard College Class- and isoform-specific hdac inhibitors and uses thereof
MA33926B1 (fr) * 2009-12-17 2013-01-02 Merck Sharp & Dohme Aminopyrimidines en tant qu'inhibiteurs de la syk
US20130040998A1 (en) 2010-01-08 2013-02-14 Dana-Farber Cancer Institute, Inc. Fluorinated hdac inhibitors and uses thereof
EP3091004B1 (en) 2010-01-22 2017-12-13 Acetylon Pharmaceuticals, Inc. Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof
EP2571352A4 (en) 2010-05-21 2014-09-17 Sloan Kettering Inst Cancer SELECTIVE HDAC HEMMER
WO2012018499A2 (en) 2010-08-05 2012-02-09 Acetylon Pharmaceuticals Specific regulation of cytokine levels by hdac6 inhibitors
EP3067346A1 (en) 2010-11-16 2016-09-14 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
WO2013013113A2 (en) 2011-07-20 2013-01-24 The General Hospital Corporation Histone deacetylase 6 selective inhibitors for the treatment of bone disease
US8841301B2 (en) * 2011-09-26 2014-09-23 Bristol-Myers Squibb Company Selective NR2B antagonists
JP5724851B2 (ja) * 2011-11-30 2015-05-27 東レ株式会社 N−(ヨードフェニル)ピリミジニルアミン誘導体の製造方法
JP2015515279A (ja) 2012-04-19 2015-05-28 アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. 治療に反応する患者を同定するバイオマーカーおよびそのような患者の治療
EP2906211A4 (en) 2012-10-12 2016-04-20 Univ Pennsylvania PYRIMIDINHYDROXY AMID COMPOUNDS AS A PROTEIN DEACETYLASE INHIBITOR AND METHOD OF USE THEREOF
US9145412B2 (en) 2012-11-02 2015-09-29 Acetylon Pharmaceuticals, Inc. Selective HDAC1 and HDAC2 inhibitors
US9096549B2 (en) 2013-02-01 2015-08-04 Acetylon Pharmaceuticals, Inc. Selective HDAC3 inhibitors
US9139583B2 (en) 2013-02-01 2015-09-22 Acetylon Pharmaceuticals, Inc. Selective HDAC3 inhibitors
JP2016523236A (ja) 2013-06-03 2016-08-08 アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. 多発性骨髄腫におけるヒストン脱アセチル化酵素(hdac)バイオマーカー
WO2015042418A1 (en) 2013-09-20 2015-03-26 Acetylon Pharmaceuticals, Inc. Treatment of diseases caused by abnormal lymphocyte function with an hdac6 inhibitor
JP6626437B2 (ja) 2013-10-08 2019-12-25 アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. ヒストンデアセチラーゼ阻害剤とHer2阻害剤またはPI3K阻害剤のいずれかの組み合わせ
US20150105383A1 (en) 2013-10-10 2015-04-16 Acetylon Pharmaceuticals, Inc. HDAC Inhibitors, Alone Or In Combination With PI3K Inhibitors, For Treating Non-Hodgkin's Lymphoma
US20150105409A1 (en) 2013-10-10 2015-04-16 Acetylon Pharmaceticals, Inc. Hdac inhibitors, alone or in combination with btk inhibitors, for treating nonhodgkin's lymphoma
WO2015054474A1 (en) 2013-10-10 2015-04-16 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors
PE20161342A1 (es) 2013-10-11 2016-12-31 Acetylon Pharmaceuticals Inc Combinaciones de inhibidores de histona desacetilasa y farmacos inmunomoduladores
JP2016534069A (ja) 2013-10-24 2016-11-04 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ Hdac6阻害剤での多嚢胞性疾患の治療
CN105939716A (zh) 2013-12-03 2016-09-14 埃斯泰隆制药公司 组蛋白脱乙酰基酶抑制剂和免疫调节药物的组合
JP7017309B2 (ja) 2013-12-20 2022-02-08 アセチロン ファーマシューティカルズ インコーポレイテッド 多発性骨髄腫におけるヒストン脱アセチル化酵素6(hdac6)バイオマーカー
US9464073B2 (en) 2014-02-26 2016-10-11 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors
US20150359794A1 (en) 2014-06-13 2015-12-17 Buck Institute For Research On Aging Impairment of the large ribosomal subunit protein rpl24 by depletion or acetylation
JP6952602B2 (ja) 2014-07-07 2021-10-20 アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. ヒストンデアセチラーゼ阻害剤による白血病の治療
EP3204006A4 (en) 2014-10-08 2018-04-04 Regenacy Pharmaceuticals, LLC Induction of gata2 by hdac1 and hdac2 inhibitors
WO2016090230A1 (en) 2014-12-05 2016-06-09 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds for treating peripheral neuropathy
US9937174B2 (en) 2014-12-05 2018-04-10 University of Modena and Reggio Emilia Combinations of histone deacetylase inhibitors and bendamustine
HK1251566A1 (zh) 2014-12-12 2019-02-01 Regenacy Pharmaceuticals, Llc 作为hdac1/2抑制剂的呱啶衍生物
US20160339022A1 (en) 2015-04-17 2016-11-24 Acetylon Pharmaceuticals Inc. Treatment of neuroblastoma with histone deacetylase inhibitors
US10272084B2 (en) 2015-06-01 2019-04-30 Regenacy Pharmaceuticals, Llc Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy
JP6816036B2 (ja) 2015-06-08 2021-01-20 アセチロン ファーマシューティカルズ インコーポレイテッドAcetylon Pharmaceuticals,Inc. ヒストン脱アセチル化阻害剤の結晶形態
WO2016200930A1 (en) 2015-06-08 2016-12-15 Acetylon Pharmaceuticals, Inc. Methods of making protein deacetylase inhibitors
JP7100018B2 (ja) 2016-08-08 2022-07-12 アセチロン ファーマシューティカルズ インコーポレイテッド ヒストンデアセチラーゼ6阻害剤及びcd20阻害抗体の薬学的組み合わせならびにその使用

Also Published As

Publication number Publication date
US10144714B2 (en) 2018-12-04
AU2020267299A1 (en) 2020-12-10
CN107922352B (zh) 2021-08-06
JP6873053B2 (ja) 2021-05-19
WO2016200930A9 (en) 2017-02-23
ES2769255T3 (es) 2020-06-25
JP2018518486A (ja) 2018-07-12
AU2016276573A1 (en) 2018-01-04
WO2016200930A1 (en) 2016-12-15
TWI706937B (zh) 2020-10-11
TW201718517A (zh) 2017-06-01
US20160355486A1 (en) 2016-12-08
CA2988594A1 (en) 2016-12-15
CN107922352A (zh) 2018-04-17
EP3303304B1 (en) 2019-11-20
EP3303304A1 (en) 2018-04-11
AU2020267299B2 (en) 2022-07-07
MX2017015900A (es) 2018-11-09
MX369349B (es) 2019-11-06
CA2988594C (en) 2023-08-15

Similar Documents

Publication Publication Date Title
AR105812A1 (es) Métodos para la preparación de inhibidores de proteína deacetilasa
CL2020002269A1 (es) Anticuerpo que se une a redil33; polinucleótido; vector; célula hospedadora; método para producir el anticuerpo; composición farmacéutica; producto de combinación; uso del anticuerpo para tratar una afección inflamatoria (divisional de la solicitud no. 201702433)
CO2018012171A2 (es) Piridinas sustituidas con heteroarilo y métodos de uso
EA201890522A1 (ru) Способ получения противогрибковых соединений
MX2020010841A (es) Composicion detergente.
EA201691649A1 (ru) Способ получения противогрибковых соединений
MX2018006148A (es) Inhibidores de cxcr2.
MX373717B (es) Composiciones concentradas para la limpieza personal y metodos.
EA201692219A1 (ru) Способы получения противовирусных соединений
CO2017002253A2 (es) Compuesto dirigido a il-23a y tnf-alfa
CL2016003301A1 (es) Compuestos derivados del ácido amino-(piridin-4-carboxílico) sustituidos, inhibidores de la histona desmetilasa; composición farmacéutica, que los comprende, útiles en el tratamiento del cáncer, tales como el cáncer de próstata, mama, vejiga, pulmón y/o melanoma.
EA201490458A1 (ru) Способ получения тернесита
DOP2017000278A (es) Piridinas sustituidas y método de uso
MX392317B (es) Proceso para la preparación de etilenglicol a partir de azúcares.
EA201691648A1 (ru) Способ получения противогрибковых соединений
AR100232A1 (es) Detergente
EP3504185A4 (en) NEW SUBSTITUTED N'-HYDROXYCARBAMIMIDOYL-1,2,5-OXADIAZOLE COMPOUNDS AS INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE (IDO)
BR112019025028A2 (pt) Método para preparar um composto.
CO2018010694A2 (es) Una composición de componente único o múltiple para la producción de un hidrogel
MX2022007670A (es) Compuestos antihelminticos que comprenden una estructura de quinolina.
EA201500931A1 (ru) Производные пиридин-4-ила
CL2017000484A1 (es) Compuestos de azetidiniloxifenilpirrolidina
MX387796B (es) Compuestos de aminocarbonilcarbamato.
CL2017001615A1 (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2.
DOP2017000189A (es) Compuestos de benzoxaborol y usos de los mismos